A Van Deun1, K J M Aung2, A Hossain2, P de Rijk3, M Gumusboga3, L Rigouts4, B C de Jong5. 1. Mycobacteriology Unit, Institute of Tropical Medicine, Antwerp, Belgium; International Union Against Tuberculosis and Lung Disease, Paris, France. 2. Damien Foundation, Dhaka, Bangladesh. 3. Mycobacteriology Unit, Institute of Tropical Medicine, Antwerp, Belgium. 4. Mycobacteriology Unit, Institute of Tropical Medicine, Antwerp, Belgium; Department of Biomedical Sciences, Antwerp, Belgium. 5. Mycobacteriology Unit, Institute of Tropical Medicine, Antwerp, Belgium; New York University, New York, New York, USA.
Abstract
SETTING: Greater Mymensingh area, Bangladesh. OBJECTIVES: To document among new tuberculosis (TB) patients the proportions and treatment outcomes of silent, non-disputed and disputed (generally missed by rapid drug susceptibility testing [DST]) rpoB mutations, and their detection by commercial molecular assays. DESIGN: Retrospective analysis of rpoB sequences from randomly selected ethanol-preserved diagnostic sputum samples; comparison of sequencing with conventional DST results and standard first-line treatment outcome; retesting of samples with mutations using the Xpert MTB/RIF and GenoType MTBDRplus assays. RESULTS: Of 1091 samples, 5.8% failed amplification, and six contained other mycobacteria. In 2005 and 2010, respectively 2/500 (0.4%) and 11/522 (2.1%) amplicons showed non-silent mutations. At least 7/13 of these belonged to the disputed group, with 5/7 patients suffering adverse treatment outcome. One silent mutation went undetected by commercial assays. Following routine DST indications, only three cases with a non-silent mutation were eventually detected. CONCLUSIONS: Disputed rpoB mutations may be responsible for the majority of rifampicin (RMP) resistance among new cases, and lead to adverse outcomes of first-line treatment. Silent mutations do not necessarily cause Xpert or line-probe assay false RMP-resistant results. Molecular RMP DST could greatly simplify resistance surveillance, in addition to offering the best prospects for early and accurate individual diagnosis.
SETTING: Greater Mymensingh area, Bangladesh. OBJECTIVES: To document among new tuberculosis (TB) patients the proportions and treatment outcomes of silent, non-disputed and disputed (generally missed by rapid drug susceptibility testing [DST]) rpoB mutations, and their detection by commercial molecular assays. DESIGN: Retrospective analysis of rpoB sequences from randomly selected ethanol-preserved diagnostic sputum samples; comparison of sequencing with conventional DST results and standard first-line treatment outcome; retesting of samples with mutations using the Xpert MTB/RIF and GenoType MTBDRplus assays. RESULTS: Of 1091 samples, 5.8% failed amplification, and six contained other mycobacteria. In 2005 and 2010, respectively 2/500 (0.4%) and 11/522 (2.1%) amplicons showed non-silent mutations. At least 7/13 of these belonged to the disputed group, with 5/7 patients suffering adverse treatment outcome. One silent mutation went undetected by commercial assays. Following routine DST indications, only three cases with a non-silent mutation were eventually detected. CONCLUSIONS: Disputed rpoB mutations may be responsible for the majority of rifampicin (RMP) resistance among new cases, and lead to adverse outcomes of first-line treatment. Silent mutations do not necessarily cause Xpert or line-probe assay false RMP-resistant results. Molecular RMP DST could greatly simplify resistance surveillance, in addition to offering the best prospects for early and accurate individual diagnosis.
Authors: Sophia B Georghiou; Marva Seifert; Donald G Catanzaro; Richard S Garfein; Timothy C Rodwell Journal: J Clin Microbiol Date: 2017-04-12 Impact factor: 5.948
Authors: Margaretha de Vos; Brigitta Derendinger; Tania Dolby; John Simpson; Paul D van Helden; John E Rice; Lawrence J Wangh; Grant Theron; Robin M Warren Journal: J Clin Microbiol Date: 2018-08-27 Impact factor: 5.948
Authors: Martin Hunt; Brice Letcher; Kerri M Malone; Giang Nguyen; Michael B Hall; Rachel M Colquhoun; Leandro Lima; Michael C Schatz; Srividya Ramakrishnan; Zamin Iqbal Journal: Genome Biol Date: 2022-07-05 Impact factor: 17.906
Authors: N N Abanda; J Y Djieugoué; V S Khadka; E W Pefura-Yone; W F Mbacham; G Vernet; V M Penlap; Y Deng; S I Eyangoh; D W Taylor; R G F Leke Journal: Clin Microbiol Infect Date: 2017-12-05 Impact factor: 8.067